Qiagen N.V. (QGEN)

$48.57 +0.25 (0.52%)
Market Cap 10.26B
Revenue (ttm) 2.09B
Net Income (ttm) 424.88M
EPS (ttm) N/A
PE Ratio 19.54
Forward PE 19.33
Profit Margin 20.33%
Debt to Equity Ratio 0.44
Volume 1,643,300
Avg Vol 2,255,376
Day's Range N/A - N/A
Shares Out 211.18M
Stochastic %K 14%
Beta 0.67
Analysts Sell
Price Target $55.09

Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 31 77 355 6600
Address:
Hulsterweg 82, Venlo, Netherlands
SuperGreenToday
SuperGreenToday Feb. 19 at 2:36 AM
$QGEN Share Price: $49.01 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $1.74 – $2.15 Target Zone: $3.32 – $4.06 Potential Upside: 80% ROI Time to Expiration: 119 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Feb. 6 at 1:17 PM
$QGEN dips 0.9% despite solid Q4 revenue beat 📉 🔹 Q4 net sales up 3.7%, beating Zacks Consensus by 2.36% 🔹 Sample Technologies revenue jumped 8% on a reported basis 🔹 Challenges ahead with contracting margins & cautious 2026 outlook Opportunity assessment here 👉 https://www.zacks.com/stock/news/2835651/qgens-q4-earnings-meet-estimates-revenues-up-yy-stock-down?cid=sm-stocktwits-2-2835651-body-32255&ADID=SYND_STOCKTWITS_TWEET_2_2835651_BODY_32255
0 · Reply
ZacksResearch
ZacksResearch Feb. 6 at 12:17 PM
$QGEN reports Q4 — and the stock sells off anyway. ⚠️ Q4 earnings met estimates and revenues were up year over year, despite the stock trading lower after the report — a reminder that results alone don’t always drive price action. Find out what’s pressuring the stock here 👉 https://www.zacks.com/stock/news/2835651/qgens-q4-earnings-meet-estimates-revenues-up-yy-stock-down?cid=sm-stocktwits-2-2835651-teaser-32252&ADID=SYND_STOCKTWITS_TWEET_2_2835651_TEASER_32252
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 6 at 2:01 AM
$QGEN Share Price: $51.23 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $1.74 – $2.15 Target Zone: $3.09 – $3.77 Potential Upside: 67% ROI Time to Expiration: 132 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OptionRunners
OptionRunners Feb. 5 at 4:17 PM
$QGEN
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 5 at 12:30 PM
$QGEN Q4 '25 Earnings Results & Recap For 2026, QIAGEN expects net sales growth of at least 5% CER, with adjusted diluted EPS of at least $2.50 CER. The adjusted operating income margin is expected to remain steady compared to 2025.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 5:19 PM
$QGEN Current Stock Price: $51.92 Contracts to trade: $50.0 QGEN Feb 20 2026 Call Entry: $2.30 Exit: $4.09 ROI: 78% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Jo__Hannes
Jo__Hannes Jan. 27 at 11:23 AM
$QGEN Trading idea: Run a double put against a call with a relatively tight stop-loss to fully capitalize on the takeover or rejection. Simultaneously, place a buy order well below the stop-loss to avoid missing the reversal. https://ibb.co/mCw56Lcs
0 · Reply
Jo__Hannes
Jo__Hannes Jan. 26 at 3:44 PM
$QGEN Shares on Loan Friday 13,88 Mio Shares on Loan Today 14,78 Mio
0 · Reply
JustB4SnR1se
JustB4SnR1se Jan. 23 at 9:25 AM
$QGEN buying back in if it breaks down near 50 dollar
0 · Reply
Latest News on QGEN
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

Feb 19, 2026, 8:00 AM EST - 4 days ago

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

Qiagen N.V. (QGEN) Q4 2025 Earnings Call Transcript

Feb 5, 2026, 2:44 PM EST - 17 days ago

Qiagen N.V. (QGEN) Q4 2025 Earnings Call Transcript

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

Feb 4, 2026, 4:05 PM EST - 18 days ago

QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

Feb 3, 2026, 4:05 PM EST - 19 days ago

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

Qiagen: Takeover Optionality With A High-Quality Consumables Platform

Jan 27, 2026, 8:00 AM EST - 27 days ago

Qiagen: Takeover Optionality With A High-Quality Consumables Platform

QIAGEN Appoints Mark Stevenson to Supervisory Board

Jan 26, 2026, 4:05 PM EST - 27 days ago

QIAGEN Appoints Mark Stevenson to Supervisory Board

Qiagen Explores Possible Sale After New Buyer Talks: Report

Jan 21, 2026, 8:11 AM EST - 4 weeks ago

Qiagen Explores Possible Sale After New Buyer Talks: Report

Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports

Jan 20, 2026, 12:19 PM EST - 4 weeks ago

Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports

QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

Jan 19, 2026, 9:56 AM EST - 5 weeks ago

QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

Qiagen N.V. (QGEN) Presents at 44th Annual J.P.

Jan 13, 2026, 9:26 AM EST - 5 weeks ago

Qiagen N.V. (QGEN) Presents at 44th Annual J.P.

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

Jan 12, 2026, 2:00 AM EST - 6 weeks ago

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

Dec 18, 2025, 11:27 AM EST - 2 months ago

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 6:33 PM EST - 2 months ago

Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 2:53 PM EST - 2 months ago

Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion Transcript

Nov 21, 2025, 1:33 PM EST - 3 months ago

Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion Transcript

Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 12:23 PM EST - 3 months ago

Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 3:07 PM EST - 3 months ago

Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

Nov 10, 2025, 1:30 AM EST - 3 months ago

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

Seattle's Parse Biosciences to be acquired by Qiagen for $225M

Nov 6, 2025, 1:49 PM EST - 3 months ago

Seattle's Parse Biosciences to be acquired by Qiagen for $225M

Qiagen N.V. (QGEN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 3:51 PM EST - 3 months ago

Qiagen N.V. (QGEN) Q3 2025 Earnings Call Transcript

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

Nov 4, 2025, 1:04 PM EST - 3 months ago

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

Nov 4, 2025, 1:03 PM EST - 3 months ago

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

Oct 28, 2025, 5:05 PM EDT - 4 months ago

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

Oct 13, 2025, 8:24 AM EDT - 4 months ago

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 25, 2025, 10:57 AM EDT - 5 months ago

Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

Sep 10, 2025, 4:05 PM EDT - 5 months ago

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Prepared Remarks Transcript

Sep 10, 2025, 4:03 PM EDT - 5 months ago

Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Prepared Remarks Transcript

Qiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 5:01 PM EDT - 5 months ago

Qiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

Sep 2, 2025, 1:30 AM EDT - 6 months ago

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

Aug 28, 2025, 5:08 PM EDT - 6 months ago

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

Aug 28, 2025, 12:11 PM EDT - 6 months ago

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

Aug 28, 2025, 2:05 AM EDT - 6 months ago

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

Aug 21, 2025, 9:52 AM EDT - 6 months ago

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:44 PM EDT - 7 months ago

Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

Aug 5, 2025, 4:05 PM EDT - 7 months ago

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

Jul 22, 2025, 4:05 PM EDT - 7 months ago

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

Jul 8, 2025, 5:44 AM EDT - 8 months ago

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

Jun 26, 2025, 1:16 PM EDT - 8 months ago

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

Qiagen and Gencurix Enter Clinical Diagnostics Partnership

Jun 18, 2025, 4:38 PM EDT - 8 months ago

Qiagen and Gencurix Enter Clinical Diagnostics Partnership

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

Jun 18, 2025, 4:05 PM EDT - 8 months ago

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Jun 15, 2025, 4:00 AM EDT - 9 months ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

INCY

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

Jun 5, 2025, 6:20 PM EDT - 9 months ago

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

Jun 2, 2025, 2:05 PM EDT - 9 months ago

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

Jun 2, 2025, 1:00 PM EDT - 9 months ago

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

May 22, 2025, 4:05 PM EDT - 9 months ago

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential

May 15, 2025, 7:30 AM EDT - 10 months ago

Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

May 12, 2025, 4:05 PM EDT - 10 months ago

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:48 PM EDT - 10 months ago

Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript

QIAGEN announces plans for transition in leadership of Supervisory Board

May 7, 2025, 4:20 PM EDT - 10 months ago

QIAGEN announces plans for transition in leadership of Supervisory Board

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

May 7, 2025, 4:05 PM EDT - 10 months ago

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

SuperGreenToday
SuperGreenToday Feb. 19 at 2:36 AM
$QGEN Share Price: $49.01 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $1.74 – $2.15 Target Zone: $3.32 – $4.06 Potential Upside: 80% ROI Time to Expiration: 119 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Feb. 6 at 1:17 PM
$QGEN dips 0.9% despite solid Q4 revenue beat 📉 🔹 Q4 net sales up 3.7%, beating Zacks Consensus by 2.36% 🔹 Sample Technologies revenue jumped 8% on a reported basis 🔹 Challenges ahead with contracting margins & cautious 2026 outlook Opportunity assessment here 👉 https://www.zacks.com/stock/news/2835651/qgens-q4-earnings-meet-estimates-revenues-up-yy-stock-down?cid=sm-stocktwits-2-2835651-body-32255&ADID=SYND_STOCKTWITS_TWEET_2_2835651_BODY_32255
0 · Reply
ZacksResearch
ZacksResearch Feb. 6 at 12:17 PM
$QGEN reports Q4 — and the stock sells off anyway. ⚠️ Q4 earnings met estimates and revenues were up year over year, despite the stock trading lower after the report — a reminder that results alone don’t always drive price action. Find out what’s pressuring the stock here 👉 https://www.zacks.com/stock/news/2835651/qgens-q4-earnings-meet-estimates-revenues-up-yy-stock-down?cid=sm-stocktwits-2-2835651-teaser-32252&ADID=SYND_STOCKTWITS_TWEET_2_2835651_TEASER_32252
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 6 at 2:01 AM
$QGEN Share Price: $51.23 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $1.74 – $2.15 Target Zone: $3.09 – $3.77 Potential Upside: 67% ROI Time to Expiration: 132 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OptionRunners
OptionRunners Feb. 5 at 4:17 PM
$QGEN
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 5 at 12:30 PM
$QGEN Q4 '25 Earnings Results & Recap For 2026, QIAGEN expects net sales growth of at least 5% CER, with adjusted diluted EPS of at least $2.50 CER. The adjusted operating income margin is expected to remain steady compared to 2025.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 5:19 PM
$QGEN Current Stock Price: $51.92 Contracts to trade: $50.0 QGEN Feb 20 2026 Call Entry: $2.30 Exit: $4.09 ROI: 78% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Jo__Hannes
Jo__Hannes Jan. 27 at 11:23 AM
$QGEN Trading idea: Run a double put against a call with a relatively tight stop-loss to fully capitalize on the takeover or rejection. Simultaneously, place a buy order well below the stop-loss to avoid missing the reversal. https://ibb.co/mCw56Lcs
0 · Reply
Jo__Hannes
Jo__Hannes Jan. 26 at 3:44 PM
$QGEN Shares on Loan Friday 13,88 Mio Shares on Loan Today 14,78 Mio
0 · Reply
JustB4SnR1se
JustB4SnR1se Jan. 23 at 9:25 AM
$QGEN buying back in if it breaks down near 50 dollar
0 · Reply
smartkarma
smartkarma Jan. 23 at 1:22 AM
$QGEN | Qiagen Stock Soars Amid Takeover Buzz — Will This Time Be Different? "Qiagen shares surged over 12% on January 20, 2026, following a Bloomberg report that the European molecular diagnostics firm is evaluating strategic options, including a potential sale." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/qiagen-stock-soars-amid-takeover-buzz-will-this-time-be-different
0 · Reply
Eskayes
Eskayes Jan. 22 at 3:24 PM
$GH this is probably and unfortunately going to get acquired. The writing is on the wall in the space. Hope they don’t honestly but $EXAS, $QGEN $GRAL... Just bought more $CAI
0 · Reply
erevnon
erevnon Jan. 22 at 12:09 PM
Deutsche Bank downgrades Qiagen $QGEN from Buy to Hold and raises the price target from $52 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 21 at 9:02 PM
RECAP 1/21 Chatter: $AAPL $GOOGL + Siri revamp $MKSI + Raise Q4 outlook $QGEN + Turned down $68/sh offer Live Breaking trading news www.openoutcrier.com
0 · Reply
InItToWinIt100
InItToWinIt100 Jan. 21 at 10:21 AM
Early Pre Market Gappers & Crappers $GDXU $SHNY $SNDK $QGEN $NFLX https://www.trade-ideas.com/share.php?code=mymDW8wrPs2m2sHGNieDymD23HbLPr2W
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 20 at 9:00 PM
RECAP 1/20 Chatter: $QGEN + Weighs Strategic options $DKNG + MA Judge stops Kalshi Live Breaking trading news www.openoutcrier.com
0 · Reply
MaskedJoe
MaskedJoe Jan. 20 at 8:01 PM
$QGEN February 20 $55 puts
0 · Reply
DailyAnalysis
DailyAnalysis Jan. 20 at 7:37 PM
$QGEN is dead water. RSI 52 and Stoch 49 confirm a total momentum vacuum. With CCI hovering at 30, there’s no trend to ride. The setup screams chop—stay cash until a clear volatility expansion occurs. @DailyAnalysis
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 20 at 7:07 PM
$QGEN
0 · Reply
notreload_ai
notreload_ai Jan. 20 at 4:53 PM
$QGEN is reviewing strategic options, including a possible sale, as takeover interest resurfaces in the fast-growing life sciences and diagnostics sector. https://notreload.xyz/qiagen-weighs-sale-as-takeover-interest-returns/
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 20 at 4:48 PM
$QGEN
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 14 at 5:55 PM
$QGEN Current Stock Price: $47.05 Contracts to trade: $45 QGEN Jan 16 2026 Call Entry: $1.45 Exit: $2.05 ROI: 42% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply